Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year, Long-Term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin 2025, 9 (2), s532. https://doi.org/10.25251/skin.10.supp.532.